Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia)

• Published in: Epidemiology and Vaccine Prevention
• Main Authors: A. N. Argunova, Zh. V. Bondareva, E. S. Prokopiev, O. М. Nosikhina
• Format: Article in Journal/Newspaper
• Language: Russian
• Published: Numikom LLC 2018
• Subjects: пневмококковая инфекция; вакцинопрофилактика; пкв-13; Epistemology. Theory of knowledge; BD143-237; Aldan; Sakha; Sakha Republic; Yakutia
• Online Access: https://doi.org/10.31631/2073-3046-2018-17-4-38-45; https://doaj.org/article/f4a6f2ec512949f2a80a3c71614bb3c2

The pneumococcal infection is an important issue due to its prevalence, numerous severe complications, high mortality rate and disability. However modern vaccination allows preventing of the pneumococcal infection and reduces the severity of clinical complications. This article presents the analysis of the morbidity and mortality indicators from community-acquired pneumonia and the effect of pneumococcal vaccination on its dynamic in the at-risk groups within the adult population of the Aldan area and the city of Aldan of the Sakha Republic (Yakutia). In the Aldan area pneumonia morbidity persistently exceeds the national Russian average: in 2015 – 1.5 times (499.3 per 100,000 population) and in 2016 – 1.2 times (500.8 per 100,000 population). The morbidity indicators in Aldan are comparable to the national values. The community-acquired pneumonia mortality rates in the Aldan area were 20.55 per 100,000 population in 2015, and 18.5 per 100,000 population in 2016; these values are, respectively, 4.3 and 3.8 times higher than the national average. In the city of Aldan the community-acquired pneumonia mortality rates were 9.87 per 100,000 population in 2015 and 15.8 per 100,000 population in 2016, which is more than double the national average in the Russian Federation. Pneumococcal vaccinations of the adult population using the conjugate vaccine Prevenar 13 have been observed to lower the pneumonia morbidity and respiratory infections; the vaccinations also reduced the number of hospitalizations due to condition exacerbations or decompensations among adult patients with chronic lung disorders, cardiac insufficiency, and diabetes.